Kang Il Jun

Kang Il Jun

Auto-generated profile, based on publicly available information

Kang Il Jun

Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul 07804, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
WPWan Beom Park
Wan Beom Park
KJKang Il Jun
Kang Il Jun
GKGayeon Kim
Gayeon Kim
JCJae-Phil Choi
Jae-Phil Choi
JRJi-Young Rhee
Ji-Young Rhee
HSHyoung-shik Shin
Hyoung-shik Shin
Park WB, et al. J Korean Med Sci. 2018 May;33(24):e169. https://doi.org/10.3346/jkms.2018.33.e169

4 November 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BKBhumsuk Keam
Bhumsuk Keam
CKChang Kyung Kang
Chang Kyung Kang
KJKang Il Jun
Kang Il Jun
SMSong Mi Moon
Song Mi Moon
KSKoung Jin Suh
Koung Jin Suh
MOMyoung-Don Oh
Myoung-Don Oh
Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs; n = 46) or cytotoxic agents (n = 90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results support annual influenza vaccinations for cancer patients receiving ICIs. Clinical Trials Registration clinicaltrials.gov (NCT03590808).

30 April 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
JKJeong-Han Kim
Jeong-Han Kim
TKTaek Soo Kim
Taek Soo Kim
HJHyun Gul Jung
Hyun Gul Jung
CKChang Kyung Kang
Chang Kyung Kang
KJKang-Il Jun
Kang-Il Jun
MOMyoung-Don Oh
Myoung-Don Oh
Objectives: MALDI-TOF MS has been successfully used for empirical antibiotic selection. However, limited data are available regarding the usefulness of MALDI-TOF MS in common resistant organisms compared with rapid antimicrobial susceptibility testing (AST). We prospectively evaluated the usefulness of rapid AST, compared with MALDI-TOF MS, for optimal antibiotic selection by infectious disease (ID) physicians in patients with bacteraemia including polymicrobial infection. Methods: Three hundred and fifty-nine patients with positive blood culture were included for analysis. ID physicians prospectively decided on antibiotic regimens with consensus at each timepoint of receiving results of Gram stain, MALDI-TOF MS and rapid AST, the last of which was performed using QMAC-dRAST. Results: ID physicians with MALDI-TOF MS results chose optimal targeted antibiotics in 255 (71.0%) cases, with appropriate antibiotic selection in 303 (84.4%) cases. The proportion of optimal targeted antibiotic selection and appropriate antibiotic selection was significantly lower for resistant strains than for susceptible strains [62.5% versus 79.2% (P < 0.001) and 68.2% versus 100% (P < 0.001), respectively]. QMAC-dRAST results led to optimal antibiotic treatment in 95 (91.3%) of the 104 cases receiving non-optimal targeted antibiotics. Optimal targeted treatments based on QMAC-dRAST results were possible in 322 (98.2%) of the 328 cases with monobacterial infection and in 345 (96.1%) of the 359 cases with monobacterial and polymicrobial infection. Conclusions: MALDI-TOF MS has a high chance of failure in guiding ID physicians to optimal antibiotics, especially against resistant organisms. With increasingly common resistant organisms, rapid AST is needed to identify optimal targeted antibiotics early in bacteraemia.

28 August 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JKJeong-Han Kim
Jeong-Han Kim
EKEu Suk Kim
Eu Suk Kim
KJKang-Il Jun
Kang-Il Jun
HJHyungul Jung
Hyungul Jung
JBJi Hwan Bang
Ji Hwan Bang
SPSang-Won Park
Sang-Won Park
Tuberculosis (TB), especially extrapulmonary tuberculosis (EPTB), is an important cause of fever of unknown origin (FUO) in TB-burdened areas. Little information is known about patients with EPTB with clinical features presenting as FUO and about the factor of delaying the diagnosis. We retrospectively analyzed EPTB patients who were referred with FUO at 3 university-affiliated hospitals over 8 years (2010–2017). The subjects were assigned to groups of early diagnosis and delayed diagnosis within 3 days of an initial comprehensive evaluation from the referral. Clinical and laboratory variables were compared between the groups. A total of 95 patients with febrile EPTB were included. Localizing symptoms and/or signs suggestive of anatomy were identified in 62.1% of the patients. Concurrent lung involvement by TB was presented by 49.5% (47/95) of the patients, and only 23.4% of them showed typical findings of pulmonary TB on simple chest X-ray. Most of the patients showed abnormal lesions on cross-sectional CT (98.9%) and MRI (100%). The clinical variables and blood test results of patients were not significantly different between the two groups. The less typical imaging finding of EPTB on CT (38.5% vs. 79.0%) and MRI (37.5% vs. 79.0%) in the delayed diagnosis group was a risk factor for delayed diagnosis. Febrile EPTB referred as FUO showed nonspecific clinical manifestations. The active application of cross-sectional imaging tests according to clinical clues or randomly in the absence of local manifestations, combined with invasive diagnostic approaches even for atypical presentations may lead to an earlier diagnosis of febrile EPTB.

12 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CKChung-Jong Kim
Chung-Jong Kim
JBJi Yun Bae
Ji Yun Bae
KJKang-Il Jun
Kang-Il Jun
HCHae-Sun Chung
Hae-Sun Chung
AKAeyeon Kim
Aeyeon Kim
HCHee Jung Choi
Hee Jung Choi
We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test was performed, and the measles vaccine was administered to participants who tested negative or equivocal for mIgG-Abs. During the study, 2885 (87.3%) of the 3303 employees were tested for measles serostatus. The baseline seropositivity rate for mIgG-Abs was 91.9%. Among the 234 seronegative cases, 82.9% were born after 1985. The seroprevalence rate was lower in those who received the measles–mumps–rubella (MMR) vaccine >10 years before the testing time, especially if they were born after 1985 and if there was only one previous record of vaccination. Among the 234 seronegative cases, MMR vaccination was administered in 174 cases, of which serostatus was evaluated in 146 cases. After the first dose, positive seroconversion was achieved in 126 participants (86.3%). After a second dose, 15 achieved (75.0%) positive seroconversion. In healthcare personnel born after the period when measles incidence significantly decreased, it may be necessary to reassess their immune status for measles if more than 10 years have elapsed since the last vaccination.

1 January 2020 in Infection & Chemotherapy
Verified
Journal Article
Open access
JSJun-Won Seo
Jun-Won Seo
KKKichun Kim
Kichun Kim
KJKang Il Jun
Kang Il Jun
CKChang Kyung Kang
Chang Kyung Kang
SMSong Mi Moon
Song Mi Moon
MOMyoung-Don Oh
Myoung-Don Oh
Seo JW, et al. Infect Chemother. 2020 Sep;52(3):381-388. https://doi.org/10.3947/ic.2020.52.3.381